ANDA For Generic Epilepsy Drug Spurs Suit Against IVAX
The suit alleges Florida-based IVAX infringed its patent by filing an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to produce Levetiracetam, the active ingredient in Keppra.
Compelled by the Hatch-Waxman Act, IVAX informed UCB of its intentions to produce the 250 mg 500 mg and 750 mg tablets through a notice of...
Already a subscriber? Click here to login